title: Anticoagulation with warfarin for Budd-Chiari syndrome with chronic inferior vena cava thrombosis: an initial clinical experience.
abstract: BACKGROUND
  To evaluate the initial clinical safety and feasibility of anticoagulation using warfarin for Budd-Chiari syndrome (BCS) with chronic inferior vena cava (IVC) thrombosis.
  
  
  METHODS
  Between October 2005 and June 2009, a total of 16 consecutive BCS patients with chronic IVC thrombosis were treated with warfarin. Warfarin was administered orally at 2.5 mg/d for approximately 3-12 months. Transluminal balloon dilatation of the IVC with a 30-mm balloon catheter was applied for the patients with complete resolution of the thrombus. Data relating to the technical success, angiographic results, complications, and final clinical outcome were collected retrospectively and follow-ups were performed at 1, 3, 6, and 12 months after the stent placement, and annually thereafter.
  
  
  RESULTS
  Warfarin was successfully used for anticoagulation in all patients without any complications. Patients were followed up as outpatients for 6.43 ± 2.19 months, and in 14 cases, complete disappearance of the thrombosis was achieved with successful treatment by balloon dilation. In two patients with partial resolution of the thrombosis, Z-stent placement was initiated to compress the thrombus to prevent migration of the thrombosis, followed by dilation of the IVC. During the follow-up for 20.94 ± 10.31 months after the procedure, all the IVC remained patent without complications or pulmonary embolus, and all patients were alive with resolution of symptoms at the time of this study.
  
  
  CONCLUSIONS
  The use of warfarin for anticoagulation proved to be simple, safe, and feasible for BCS with chronic IVC thrombosis.
authors.affiliation: Department of Radiology, Cancer Hospital/Cancer Institute, Fudan University, No. 270 Dong'an Road, Shanghai, People's Republic of China.
authors.forename: Xin-Hong
authors.initials: XH
authors.lastname: He
authors.forename: Wen-Tao
authors.initials: WT
authors.lastname: Li
authors.forename: Wei-Jun
authors.initials: WJ
authors.lastname: Peng
authors.forename: Yong-Dong
authors.initials: YD
authors.lastname: Li
authors.forename: Hua-Qiao
authors.initials: HQ
authors.lastname: Tan
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D006502:Budd-Chiari Syndrome / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002404:Catheterization; D002681:China; D002908:Chronic Disease; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010690:Phlebography / Q000379:methods; D012189:Retrospective Studies; D015607:Stents; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014654:Vascular Patency; D014682:Vena Cava, Inferior / Q000000981:diagnostic imaging; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D014859:Warfarin